NO20050782L - Synergistisk kombinasjon av en alfa-2-deltaligand og en PDEV-inhibitor for anvendelse i behandling av smerte - Google Patents

Synergistisk kombinasjon av en alfa-2-deltaligand og en PDEV-inhibitor for anvendelse i behandling av smerte

Info

Publication number: NO20050782L
Authority: NO; Norway
Prior art keywords: alpha; pain; treatment; delta ligand; synergistic combination
Prior art date: 2002-08-15

Application number

NO20050782A

Other languages

English (en)

Norwegian (no)

Inventor

Mark John Field

Richard Griffith Williams

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-08-15

Filing date

2005-02-14

Publication date

2005-04-08

2005-02-14 Application filed by Pfizer filed Critical Pfizer

2005-04-08 Publication of NO20050782L publication Critical patent/NO20050782L/no

Links

239000003112 inhibitor Substances 0.000 title abstract 3
239000003446 ligand Substances 0.000 title abstract 3
208000002193 Pain Diseases 0.000 title abstract 2
239000011885 synergistic combination Substances 0.000 title 1
UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 abstract 2
BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 abstract 2
SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 abstract 1
238000009109 curative therapy Methods 0.000 abstract 1
229960002870 gabapentin Drugs 0.000 abstract 1
208000004296 neuralgia Diseases 0.000 abstract 1
208000021722 neuropathic pain Diseases 0.000 abstract 1
238000002638 palliative care Methods 0.000 abstract 1
229960001233 pregabalin Drugs 0.000 abstract 1
AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 abstract 1
230000000069 prophylactic effect Effects 0.000 abstract 1
238000011321 prophylaxis Methods 0.000 abstract 1
229960003310 sildenafil Drugs 0.000 abstract 1
229960000835 tadalafil Drugs 0.000 abstract 1
IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1
229960002381 vardenafil Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Physical Education & Sports Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)
Immunology (AREA)
Gynecology & Obstetrics (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO20050782A 2002-08-15 2005-02-14 Synergistisk kombinasjon av en alfa-2-deltaligand og en PDEV-inhibitor for anvendelse i behandling av smerte NO20050782L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0219024.7A GB0219024D0 (en)	2002-08-15	2002-08-15	Synergistic combinations
PCT/IB2003/003476 WO2004016259A1 (en)	2002-08-15	2003-08-04	Synergistic combination of an alpha-2-delta ligand and a pdev inhibitor for use in the treatment of pain

Publications (1)

Publication Number	Publication Date
NO20050782L true NO20050782L (no)	2005-04-08

Family

ID=9942388

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20050782A NO20050782L (no)	2002-08-15	2005-02-14	Synergistisk kombinasjon av en alfa-2-deltaligand og en PDEV-inhibitor for anvendelse i behandling av smerte

Country Status (40)

Country	Link
EP (1)	EP1536782B1 (de)
JP (1)	JP2006502139A (de)
KR (2)	KR20070009746A (de)
CN (1)	CN1674884A (de)
AP (1)	AP2005003227A0 (de)
AR (1)	AR040871A1 (de)
AT (1)	ATE359775T1 (de)
AU (1)	AU2003249476B2 (de)
BR (1)	BR0313484A (de)
CA (1)	CA2495433A1 (de)
CR (1)	CR7687A (de)
DE (1)	DE60313330T2 (de)
DK (1)	DK1536782T3 (de)
EA (1)	EA007504B1 (de)
EC (1)	ECSP055593A (de)
ES (1)	ES2285230T3 (de)
GB (1)	GB0219024D0 (de)
GE (1)	GEP20084366B (de)
GT (1)	GT200300173A (de)
HN (1)	HN2003000247A (de)
HR (1)	HRP20050136A2 (de)
IL (1)	IL166415A0 (de)
IS (1)	IS7643A (de)
MA (1)	MA27381A1 (de)
MX (1)	MXPA05001835A (de)
NO (1)	NO20050782L (de)
NZ (1)	NZ537818A (de)
OA (1)	OA12899A (de)
PA (1)	PA8577301A1 (de)
PE (1)	PE20040992A1 (de)
PL (1)	PL375553A1 (de)
PT (1)	PT1536782E (de)
RS (1)	RS20050078A (de)
SI (1)	SI1536782T1 (de)
TN (1)	TNSN05042A1 (de)
TW (1)	TW200404531A (de)
UA (1)	UA77329C2 (de)
UY (1)	UY27936A1 (de)
WO (1)	WO2004016259A1 (de)
ZA (1)	ZA200500369B (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NI200300043A (es)	2002-03-28	2003-11-05	Warner Lambert Co	AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2DELTA.
AU2004271796A1 (en) *	2003-09-12	2005-03-24	Warner-Lambert Company Llc	Combination comprising an alpha-2-delta ligand and an SSRI and/or SNRI for treatment of depression and anxiety disorders
BRPI0414781A (pt) *	2003-09-25	2006-11-21	Warner Lambert Co	aminoácidos com afinidade para a proteìna (alfa)2(delta)
BRPI0414798A (pt)	2003-09-25	2006-11-21	Warner Lambert Co	métodos para usar aminoácidos com afinidade para a proteìna alfa2delta
GB0405200D0 (en) *	2004-03-08	2004-04-21	Pfizer Ltd	Combinations comprising alpha-2-delta ligands
US20090247743A1 (en) *	2004-07-09	2009-10-01	Pfizer Inc	Preparation of beta-amino acids having affinity for the alpha-2-delta protein
ITMI20041447A1 (it) *	2004-07-20	2004-10-20	Zambon Spa	Composizione farmaceutica comprendente gabapentina
US20090227562A1 (en) *	2004-08-10	2009-09-10	Pfizer Inc.	Combination of a Selective Noradrenaline Reuptake Unhibitor and a PDEV Inhibitor
BRPI0514983A (pt) *	2004-09-07	2008-07-01	Pfizer	combinação de um agonista do receptor 5-ht(1) e um ligante alfa-2-delta para tratamento da enxaqueca
WO2006092692A1 (en) *	2005-03-01	2006-09-08	Pfizer Limited	Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain
AU2008245836A1 (en) *	2007-04-30	2008-11-06	Adolor Corporation	Compositions of (-)-E-10-OH-NT and methods for their synthesis and use
WO2008132589A1 (en) *	2007-05-01	2008-11-06	Pfizer Limited	Combinations comprising pregabalin
US20090148532A1 (en) *	2007-12-06	2009-06-11	Venkatesh Gopi M	Preparation of controlled release skeletal muscle relaxant dosage forms
TWI531362B (zh)	2008-07-21	2016-05-01	艾爾康股份有限公司	具有治療劑遞送能力之眼科裝置
CA2805371C (en) *	2010-07-30	2017-10-31	Toray Industries, Inc.	Therapeutic agent or prophylactic agent for neuropathic pain
US9376438B2 (en)	2011-05-17	2016-06-28	Principia Biopharma, Inc.	Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
CA2836449C (en)	2011-05-17	2021-04-27	The Regents Of The University Of California	Kinase inhibitors
EA025496B1 (ru)	2011-05-17	2016-12-30	Принсипиа Биофарма Инк.	Ингибиторы тирозинкиназы
WO2013084182A1 (en) *	2011-12-08	2013-06-13	Glenmark Pharmaceuticals S.A.	Pharmaceutical composition that includes a pde4 enzyme inhibitor and an analgesic agent
ME03455B (de)	2012-09-10	2020-01-20	Principia Biopharma Inc	Pyrazolopyrimidinverbindungen als kinaseinhibitoren
US8957080B2 (en)	2013-04-09	2015-02-17	Principia Biopharma Inc.	Tyrosine kinase inhibitors
PT3107544T (pt)	2014-02-21	2021-01-05	Principia Biopharma Inc	Sais e forma sólida de um inibidor de btk
US10485797B2 (en)	2014-12-18	2019-11-26	Principia Biopharma Inc.	Treatment of pemphigus
TW201718572A (zh)	2015-06-24	2017-06-01	普林斯匹亞生物製藥公司	酪胺酸激酶抑制劑
MA45547A (fr)	2016-06-29	2019-05-08	Principia Biopharma Inc	Formulations à libération modifiée à base de 2-[3-[4-amino-3-(2-fluoro-4-phénoxy-phényl)pyrazolo[3,4-d]pyrimidine-1-yl]pipéridine-1-carbonyl]-4-méthyl-4-[4-(oxétane-3-yl)pipérazine-1-yl]pent-2-ènenitrile
TWI877239B (zh)	2019-10-14	2025-03-21	美商普林斯匹亞生物製藥公司	藉由投予(R)-2-[3-[4-胺基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧呾-3-基)哌-1-基]戊-2-烯腈來治療免疫血小板減少症之方法
JP2023511105A (ja)	2020-01-22	2023-03-16	プリンシピアバイオファーマインコーポレイテッド	２－［３－［４－アミノ－３－（２－フルオロ－４－フェノキシ－フェニル）－１ｈ－ピラゾロ［３，４－ｄ］ピリミジン－１－イル］ピペリジン－１－カルボニル］－４－メチル－４－［４－（オキセタン－３－イル）ピペラジン－１－イル］ペンタ－２－エンニトリルの結晶形態
CN114195661B (zh) *	2021-12-21	2023-12-22	苏州楚凯药业有限公司	一种苯磺酸米洛巴林的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL126999A (en) *	1996-07-24	2002-03-10	Warner Lambert Co	Pharmaceutical preparations containing isobutylgaba and its history for use in the treatment of pain
CN1131855C (zh) *	1997-12-16	2003-12-24	沃尼尔·朗伯公司	1－取代－1－氨基甲基－环烷衍生物(=加巴喷丁类似物)、其制备及其在治疗神经病方面的用途
HN2000000224A (es) *	1999-10-20	2001-04-11	Warner Lambert Co	Aminoacidos biciclicos como agentes farmaceuticos
IL139073A0 (en) *	1999-10-21	2001-11-25	Pfizer	Treatment of neuropathy
EP1313478A2 (de) *	2000-08-30	2003-05-28	Lilly Icos LLC	Verfahren zur behandlung von migräne durch verwendung von pde5-inhibitoren
SK12822003A3 (sk) *	2001-04-19	2004-04-06	Warner - Lambert Company Llc	Fúzne bicyklické alebo tricyklické aminokyseliny

2002
- 2002-08-15 GB GBGB0219024.7A patent/GB0219024D0/en not_active Ceased
2003
- 2003-04-08 UA UAA200501347A patent/UA77329C2/uk unknown
- 2003-07-11 PA PA20038577301A patent/PA8577301A1/es unknown
- 2003-08-04 DE DE60313330T patent/DE60313330T2/de not_active Expired - Fee Related
- 2003-08-04 ES ES03787957T patent/ES2285230T3/es not_active Expired - Lifetime
- 2003-08-04 GE GEAP8632A patent/GEP20084366B/en unknown
- 2003-08-04 JP JP2004528754A patent/JP2006502139A/ja not_active Withdrawn
- 2003-08-04 PT PT03787957T patent/PT1536782E/pt unknown
- 2003-08-04 AT AT03787957T patent/ATE359775T1/de not_active IP Right Cessation
- 2003-08-04 NZ NZ537818A patent/NZ537818A/en unknown
- 2003-08-04 AP AP2005003227A patent/AP2005003227A0/xx unknown
- 2003-08-04 KR KR1020077000033A patent/KR20070009746A/ko not_active Ceased
- 2003-08-04 AU AU2003249476A patent/AU2003249476B2/en not_active Ceased
- 2003-08-04 RS RSP-2005/0078A patent/RS20050078A/sr unknown
- 2003-08-04 IL IL16641503A patent/IL166415A0/xx unknown
- 2003-08-04 MX MXPA05001835A patent/MXPA05001835A/es active IP Right Grant
- 2003-08-04 PL PL03375553A patent/PL375553A1/xx not_active Application Discontinuation
- 2003-08-04 SI SI200330810T patent/SI1536782T1/sl unknown
- 2003-08-04 EP EP03787957A patent/EP1536782B1/de not_active Expired - Lifetime
- 2003-08-04 BR BR0313484-9A patent/BR0313484A/pt not_active IP Right Cessation
- 2003-08-04 HR HR20050136A patent/HRP20050136A2/xx not_active Application Discontinuation
- 2003-08-04 CA CA002495433A patent/CA2495433A1/en not_active Abandoned
- 2003-08-04 CN CNA038190737A patent/CN1674884A/zh active Pending
- 2003-08-04 KR KR1020057002450A patent/KR20050042154A/ko not_active Ceased
- 2003-08-04 WO PCT/IB2003/003476 patent/WO2004016259A1/en not_active Ceased
- 2003-08-04 DK DK03787957T patent/DK1536782T3/da active
- 2003-08-04 OA OA1200500037A patent/OA12899A/en unknown
- 2003-08-04 EA EA200500207A patent/EA007504B1/ru not_active IP Right Cessation
- 2003-08-12 UY UY27936A patent/UY27936A1/es not_active Application Discontinuation
- 2003-08-12 PE PE2003000806A patent/PE20040992A1/es not_active Application Discontinuation
- 2003-08-13 AR AR20030102933A patent/AR040871A1/es not_active Application Discontinuation
- 2003-08-14 GT GT200300173A patent/GT200300173A/es unknown
- 2003-08-14 TW TW092122363A patent/TW200404531A/zh unknown
- 2003-08-14 HN HN2003000247A patent/HN2003000247A/es unknown
2005
- 2005-01-12 IS IS7643A patent/IS7643A/is unknown
- 2005-01-14 ZA ZA200500369A patent/ZA200500369B/en unknown
- 2005-02-10 EC EC2005005593A patent/ECSP055593A/es unknown
- 2005-02-14 CR CR7687A patent/CR7687A/es not_active Application Discontinuation
- 2005-02-14 NO NO20050782A patent/NO20050782L/no not_active Application Discontinuation
- 2005-02-15 MA MA28104A patent/MA27381A1/fr unknown
- 2005-02-15 TN TNP2005000042A patent/TNSN05042A1/fr unknown

Also Published As

Publication number	Publication date
ATE359775T1 (de)	2007-05-15
PA8577301A1 (es)	2004-03-10
ECSP055593A (es)	2005-04-18
BR0313484A (pt)	2005-06-21
CN1674884A (zh)	2005-09-28
EP1536782B1 (de)	2007-04-18
GT200300173A (es)	2007-03-29
GB0219024D0 (en)	2002-09-25
DK1536782T3 (da)	2007-07-30
PT1536782E (pt)	2007-06-27
UY27936A1 (es)	2004-03-31
AU2003249476A1 (en)	2004-03-03
UA77329C2 (en)	2006-11-15
HN2003000247A (es)	2007-12-14
EA200500207A1 (ru)	2005-08-25
RS20050078A (sr)	2007-09-21
DE60313330T2 (de)	2008-01-03
JP2006502139A (ja)	2006-01-19
PE20040992A1 (es)	2004-12-29
EP1536782A1 (de)	2005-06-08
ES2285230T3 (es)	2007-11-16
NZ537818A (en)	2007-07-27
HRP20050136A2 (en)	2005-06-30
AP2005003227A0 (en)	2005-03-31
TW200404531A (en)	2004-04-01
CA2495433A1 (en)	2004-02-26
GEP20084366B (en)	2008-05-13
PL375553A1 (en)	2005-11-28
ZA200500369B (en)	2006-10-25
MA27381A1 (fr)	2005-06-01
EA007504B1 (ru)	2006-10-27
IL166415A0 (en)	2006-01-15
KR20050042154A (ko)	2005-05-04
CR7687A (es)	2005-07-08
DE60313330D1 (de)	2007-05-31
IS7643A (is)	2005-01-12
KR20070009746A (ko)	2007-01-18
MXPA05001835A (es)	2005-09-30
AU2003249476B2 (en)	2008-06-26
AR040871A1 (es)	2005-04-20
TNSN05042A1 (fr)	2007-05-14
WO2004016259A1 (en)	2004-02-26
OA12899A (en)	2006-10-13
SI1536782T1 (sl)	2007-08-31

Legal Events

Date	Code	Title	Description
2010-03-22	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20050782L (no)	2005-04-08	Synergistisk kombinasjon av en alfa-2-deltaligand og en PDEV-inhibitor for anvendelse i behandling av smerte
WO2005000213A8 (en)	2005-06-23	Method for treating diseases using hsp90-inhibiting agents in combination with enzyme inhibitors
WO2004010937A3 (en)	2004-05-27	Method of treating cancer
IS2130B (is)	2006-07-14	Glútamín-þíasólidíð og -pýrrólidíð og notkun þeirra sem dípeptidýlpeptíðasa IV hindrar
AU2003297392A1 (en)	2004-07-29	Valve and related methods for reducing fluid pressure and generating power
PL372398A1 (en)	2005-07-25	Use of il-18 inhibitors for the treatment and/or prevention of peripheral vascular diseases
MY162110A (en)	2017-05-31	Caspase inhibitors containing isoxazoline ring
NO20053042L (no)	2005-06-21	Anvendelse av spongosin (2-metoksyadenosin) for behandling av smerte, saerlig hyperalgesi.
WO2005000212A3 (en)	2005-03-24	Method for treating diseases using hsp90-inhibiting agents in combination with nuclear export inhibitors
FR2848116B1 (fr)	2007-01-05	Composition cosmetique comprenant un inhibiteur des metallo-proteinases et un lipopeptide.
AU2003231911A8 (en)	2003-12-31	Emergency medical kit, respiratory pump, and face mask particularly useful therein
AU2003253498A1 (en)	2004-01-23	Shower device with tanning device and method for use thereof
GB0322552D0 (en)	2003-10-29	Therapeutic treatment
DE60307891D1 (de)	2006-10-05	Verwendung eines akariziden pulvers
MXPA06000652A (es)	2006-03-30	Sales alcalinas de inhibidores de bomba de protones.
MXPA04011018A (es)	2005-01-25	Nueva combinacion de inhibidores reversibles de la bomba de protones y productos terapueticos para tratar trastornos de las vias respiratorias.
IL181183A (en)	2010-12-30	Use of an elastase inhibitor in the manufacture of a medicament for the treatment of leukemia
DOP2003000667A (es)	2004-02-29	Combinaciones sinergicas
AU2003292132A1 (en)	2004-05-13	Use of pyrimethanil on resistant pathogens
TW200642688A (en)	2006-12-16	New use of PDE7 inhibitors
AU2003294057A1 (en)	2004-06-23	Use of canthin-6-one, plant extracts containing same and derivatives thereof in the treatment of trypanosomiases
PL370839A1 (en)	2005-05-30	Use of proton pump inhibitors for the treatment of airway disorders
DE602004022463D1 (de)	2009-09-17	Verwendung eines PDE5-Hemmers zur Behandlung und Vorbeugung von Hypopigmentierungsstörungen
AR112121A1 (es)	2019-09-25	Producto de combinación farmacéutico que comprende toxina botulínica para el tratamiento de la disfunción eréctil
MXPA05011593A (es)	2005-12-15	Composicion farmaceutica que comprende un inhibidor de catepsina s y un opioide.